Effects of a Weight Loss Program on Metabolic Syndrome, Eating Disorders and Psychological Outcomes: Mediation by Endocannabinoids?

Détails

Ressource 1Télécharger: PMID29631275.pdf (1148.71 [Ko])
Etat: Serval
Version: Final published version
ID Serval
serval:BIB_55582CAD6D45
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Effects of a Weight Loss Program on Metabolic Syndrome, Eating Disorders and Psychological Outcomes: Mediation by Endocannabinoids?
Périodique
Obesity facts
Auteur(s)
Pataky Z., Carrard I., Gay V., Thomas A., Carpentier A., Bobbioni-Harsch E., Golay A.
ISSN
1662-4033 (Electronic)
ISSN-L
1662-4025
Statut éditorial
Publié
Date de publication
2018
Peer-reviewed
Oui
Volume
11
Numéro
2
Pages
144-156
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
To evaluate the effects of weight loss on endocannabinoids, cardiometabolic and psychological parameters, eating disorders (ED) as well as quality of life (QoL) and to elucidate the role of endocannabinoids in metabolic syndrome (MS).
In total, 114 patients with obesity were prospectively included in a 12-month weight loss program. Plasma endocannabinoids were measured by mass spectrometry; ED, psychological and QoL-related parameters were evaluated by self-reported questionnaires; physical activity was measured by accelerometer. Nutritional assessment was done by a 3-day food diary.
Among completers (n = 87), body weight decreased in 35 patients (-9.1 ± 8.6 kg), remained stable in 39 patients, and increased in 13 patients (+5.8 ± 3.4 kg). 75% of patients with MS at baseline were free of MS at follow-up, and their baseline plasma N-palmitoylethanolamide (PEA) values were significantly lower when compared to patients with persisting MS. At baseline, there was a positive relationship between PEA and waist circumference (p = 0.005, R2 = 0.08), fasting glucose (p < 0.0001, R2 = 0.12), total cholesterol (p = 0.001, R2 = 0.11), triglycerides (p = 0.001, R2 = 0.11), LDL-cholesterol (p = 0.03, R2 = 0.05) as well as depression score (p = 0.002, R2 = 0.29).
Plasma PEA might play a role in metabolic improvement after weight loss. Even in subjects without weight loss, a multidisciplinary intervention improves psychological outcomes, ED, and QoL.
Mots-clé
Eating disorders, Endocannabinoids, Metabolic syndrome, Patient education, Quality of life, Weight loss
Pubmed
Web of science
Open Access
Oui
Création de la notice
15/06/2018 9:42
Dernière modification de la notice
08/05/2019 18:47
Données d'usage